Franklin Biotechnology Discovery A $

Investment Objective To seek long-term investment growth, through growth of capital. Investment Policy The Fund mainly invests in equities of biotechnology companies and discovery research firms of any market capitalisation. This may include companies involved with genomics, genetic engineering and gene therapy as well as companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. These investments may be from anywhere in the world, although the Fund may invest significantly in the US.To a lesser extent, the Fund may invest in corporate bonds, private companies, private investments in public equity (PIPEs) and special purpose acquisition companies (SPACs).SFDR category Article 8 (promotes environmental and/or social characteristics under EU regulations).The investment manager applies a proprietary rating methodology using various ESG criteria to assess long-term opportunities and risks. The Fund favours issuers with a high or improving profile and excludes or restricts investments in certain industries that are harmful to the environment or society, such as thermal coal, weapons and tobacco. The investment manager engages in dialogue with companies concerning ESG issues.For more information see www.franklintempleton.lu/4912Benchmark(s) NASDAQ Biotechnology Index. Used for performance comparison only.The Fund is actively managed and may deviate materially from that of the benchmark(s).Base currency US dollar (USD). Share Class Policy Buying and selling shares You may normally buy or sell shares on any day the New York Stock Exchange is open for business. The income received from the Fund's investments is accumulated with the result of increasing the value of the shares.

PIR compliant

No

PEA compliant

No

PEA-PME compliant

No